We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gene Biomarker May Predict Sudden Heart Failure

By LabMedica International staff writers
Posted on 13 Sep 2012
A blood test can predict who would benefit from Implantable Cardioverter Defibrillators (ICD), which are surgically implanted in heart failure patients to prevent sudden death,

The straightforward laboratory test can tell with high accuracy which patients will or will not require an ICD for the next 12 months that would prevent arrhythmia and its subsequent cardiac arrest. More...


Physicians at the Chicago College of Medicine (IL, USA) carried out a clinical trial on 180 adults participants of whom 135 of them had heart failure, and 45 were healthy individuals as the control group. They excluded people with inflammatory conditions, infections, and congenital heart disease. The blood test, called PulsePredic, detects alterations in the messenger ribonucleic acid (mRNA) for the sodium channel, voltage-gated, type V, alpha subunit (SCN5A) gene, which previous studies have shown to be closely linked with sudden death. The increase in the altered mRNA was found to be a good predictor of which patients were most likely to have a sudden death episode requiring defibrillation.

The scientists measured the SCN5A gene in white blood cells and heart muscle cells. By analyzing the alterations in the mRNA, they could predict who would have a sudden death episode where defibrillation would be required. The patients with heart failure who had arrhythmias that would cause sudden death were found to have considerably higher levels of these genetic mutations, compared to those with normal heartbeats. By measuring variant levels in the blood, they were able to predict surprisingly accurately who had arrhythmic risk, suggesting that it is possible to have a blood test for sudden death risk and the need for an ICD.

Certain proteins, called voltage-gated sodium channels, are responsible for generating the main current for the electrical signals in the heart. The SCN5A gene encodes for these proteins. Arrhythmias occur when there are rises or falls in the sodium current. Samuel C. Dudley, MD, PhD, chief cardiologist at the University of Illinois (Chicago, IL, USA), explained, “The test predicts whether you will have sudden death from heart failure and whether you will need a defibrillator in the next year." Professor Dudley is the CEO of ROS Technologies, Inc., the university’s spinoff company that will develop the blood test. The study was presented at the European Society of Cardiology Congress 2012, held in Munich (Germany).

Related Links:

Chicago College of Medicine
University of Illinois




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Urine Analyzer
respons® UDS100
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.